Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-VALPROIC ACID | 250MG | CAPSULE | Resolved | 2022-09-23 | 2023-05-12 | 170115 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Actual shortage | 2023-06-09 | 2024-12-05 | 194593 |
| APO-VALPROIC SYRUP | 50MG | SYRUP | Resolved | 2017-07-11 | 2017-08-18 | 15412 |
| APO-VALSARTAN | 80MG | TABLET | Resolved | 2017-03-10 | 2019-03-08 | 272 |
| APO-VALSARTAN | 160MG | TABLET | Resolved | 2017-03-11 | 2019-03-08 | 549 |
| APO-VALSARTAN | 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-11 | 570 |
| APO-VALSARTAN | 40MG | TABLET | Resolved | 2017-03-11 | 2019-03-11 | 573 |
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 263 |
| APO-VALSARTAN/HCTZ | 12.5MG 80MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 266 |
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Resolved | 2017-03-10 | 2019-03-21 | 269 |
| APO-VALSARTAN/HCTZ | 25MG 160MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 546 |
| APO-VALSARTAN/HCTZ | 12.5MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 564 |
| APO-VALSARTAN/HCTZ | 25MG 320MG | TABLET | Resolved | 2017-03-11 | 2019-03-21 | 567 |
| APO-VARDENAFIL | 5MG | TABLET | Resolved | 2021-05-25 | 2021-11-01 | 139854 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2021-05-25 | 2021-11-02 | 139857 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2021-04-05 | 2021-10-25 | 136817 |
| APO-VARDENAFIL | 10MG | TABLET | Resolved | 2020-04-13 | 2020-05-11 | 111960 |
| APO-VARDENAFIL | 20MG | TABLET | Resolved | 2020-04-15 | 2020-05-11 | 112198 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2019-10-30 | 2019-11-18 | 97477 |
| APO-VARENICLINE | 0.5MG | TABLET | Resolved | 2020-02-05 | 2020-03-27 | 105367 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |